DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potential treatment of stroke.
The research program has now become Algernon’s lead drug asset, following the sale of its Ifenprodil research program to the U.S. private drug development firm Seyltx this March.
Get the latest on cannabis research at our upcoming Benzinga Cannabis Capital Conference!
The company established Algernon NeuroScience -or AGN Neuro- to advance R&D on the DMT stroke program in 2023. The wholly-owned subsidiary completed a feasibility study and has the expected Phase 2a clinical trial design …